Reverse Phase Protein Microarray Technology: Advances into the Clinical Research Arena

Emanuel F. Petricoin*, Brian Leyland-Jones, Julie Wulfkuhle, Marielena Pierobon, Claudius Mueller, Virginia Espina, Lance A. Liotta

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Reverse phase protein microarray(s) (RPMA) is a proteomic technology that can generate a quantitative, precise, and highly sensitive profile of hundreds of protein and phosphoprotein endpoints from a very small input of tissue or cells. Herein we review the history of RPMA creation and development and show how this special platform has graduated from the research lab to the clinical trial arena. RPMA technology is now being used to gather data from human clinical core needle specimens before and after molecular-targeted therapy. RPMA is also being used in combination with genomic analysis for the individualized selection of therapy for stage IV breast cancer. RPMA technology generates data that can be used to visualize activated protein pathways and functional interconnections both inside and outside a cell. This information will be critical to realize the goal of individualized therapy tailored to the functional molecular network of the diseased cells.

Original languageEnglish
Title of host publicationProteomic and Metabolomic Approaches to Biomarker Discovery
PublisherElsevier Inc.
Number of pages13
ISBN (Print)9780123944467
StatePublished - Jun 2013
Externally publishedYes


  • Cancer
  • Individualized therapy
  • Kinase pathways
  • Protein arrays
  • Reverse phase
  • Signal transduction


Dive into the research topics of 'Reverse Phase Protein Microarray Technology: Advances into the Clinical Research Arena'. Together they form a unique fingerprint.

Cite this